BiomX (PHGE) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Conference overview

• Over 600 companies presented across sectors including life sciences, fintech, technology, clean tech, and mining.

• Multiple sector tracks and live/streaming sessions were available from September 9th-11th, 2024.

• HC Wainwright covers 636+ companies with 24 senior analysts.

Recent strategic developments

• Completed merger with Adaptive Phage Therapeutics and secured $50 million in financing.

• Positioned as a leader in the phage therapy space with two Phase II programs.

• Received nearly $40 million in non-dilutive funding from the Defense Health Agency.

Clinical pipeline and milestones

• Two main programs: cystic fibrosis (CF) and diabetic foot osteomyelitis (DFO), both in Phase II.

• CF program targets Pseudomonas aeruginosa infections, with a $1.5B+ commercial opportunity.

• DFO program targets Staph aureus, with a $2B+ market potential; BX211 readout expected Q1 2025.

• Cash runway extends through end of 2025.